SPECIAL REPORT – With new funding Numinus Wellness Inc. is set to become a market leader in developing psychedelic-assisted therapies - (TSX-V:NUMI)

By James Moore




The same is true for the world’s most successful and innovative companies.

Both are often regarded as “lucky,” but the truth is they spot potential early.

Both move fast to capitalise on shifting market dynamics and global policy changes.

Both position themselves in the right way, ahead of the game.

But this vision alone does not guarantee success.

Consistently picking winners in the penny share world also requires a disciplined approach.

It’s all too easy to get swept up in the emotion of an entrepreneur’s grand plan.

However, the cold hard fact remains that start-ups need working capital to fulfil their potential.

No matter how good the idea, if a company is underfunded, its chances of making it big fall dramatically.

Smart investors know this, which is why they pay such close attention to who is raising money.

The nature of a company’s funding reveals so much about the underlying business.

Numinus Wellness Inc. (TSX-V:NUMIis a perfect case in point.

Having raised $6 million at 25 cents a share just before it came to market in March, the company is now following up with a $4 million raise at 27 cents.

For investors this presents an exceptional opportunity.

Once Numinus (TSX-V:NUMIcloses the latest round, this Vancouver-based trailblazer will find itself extremely well funded to carve out a prominent position in the exciting, emerging world of psychedelic-assisted therapies.

From depression to addiction, the untapped commercial potential for these treatments is staggering.

For the first time in human history, psychedelic-assisted therapies are being brought into the mainstream.

This sea change in attitude has only been made possible by very recent changes in the regulatory environment.

This is now opening up a gigantic new global market and Numinus (TSX-V:NUMIis seizing the initiative.

READ OUR SPECIAL REPORT -To discover how Numinus’ (TSX-V:NUMI) expert team is at the forefront of developing healing treatments for the mind

Psilocybin – at the heart of Numinus’ (TSX-V:NUMI) strategy. Learn more about its commercial potential in our special report.

One of the keys to Numinus’ (TSX-V:NUMI) future momentum will be the research it conducts into psilocybin.

Produced by over 200 species of mushroom, this naturally-occurring chemical is becoming a cornerstone of psychedelic-assisted therapies.

In early June, Numinus (TSX-V:NUMI) became the first publicly-traded company in Canada to win approval to conduct research to standardize the extraction of psilocybin from mushrooms.

This was a vitally important step forward.

Scientists have known for years the revolutionary potential for hallucinogens to improve mental wellbeing.

But, it took decades of tightly controlled research before regulators were ready to accept their use. 

Since 2018, there has been a significant increase in research around the use of psychedelic substances for therapy.

Once the first clinical trials began, the floodgates were opened and tens of millions of dollars flowed into research projects.

One of the most influential clinical studies into psychedelic compounds, completed in December 2019 by Compass Pathways, found psilocybin to be safe for human consumption. 

The London-based mental health start-up wanted to investigate the use of psilocybin as a treatment for depression.

In parallel, the U.S. Food and Drug Administration (FDA) designated “breakthrough therapy” status to two other drug discovery projects involving psilocybin.

The pace of this development opens up a major market opportunity for Numinus (TSX-V:NUMI).

To discover how Numinus’ (TSX-V:NUMI) expert team is at the forefront of developing healing treatments for the mind, DOWNLOAD OUR EXCLUSIVE REPORT

One of the main reasons Numinus (TSX-V:NUMIis so well placed to capitalise on the anticipated growth in psychedelic-assisted therapies is its research pedigree. 

Leading the firm’s clinical team as Chief Medical Officer is Dr Evan Wood MD, PhD, ABIM, FASAM, FRCPC, ABAM Diplomat.

As Professor of Medicine at the University of British Columbia (UBC), Wood helps lead efforts in addiction prevention and treatment through a Tier 1 Canada Research Chair. These positions are reserved for outstanding researchers who are acknowledged by their peers as world leaders in their fields. 

Numinus (TSX-V:NUMIcould hardly have chosen a more decorated or respected scientist to lead efforts to grow the company in Canada and beyond. 

As Executive Director of the British Columbia Centre on Substance Use (BCCSU), Dr. Wood’s work is recognized worldwide.  

He was also the founder of the International Centre for Science in Drug Policy, has been widely quoted by international news organizations and has co-authored more than 400 scientific papers. 

In June 2018, Wood, in partnership with Canopy Growth, UBC and BCCSU, oversaw the creation of Canada’s first professorship of cannabis science, to investigate the role that the drug could play in the mitigation of the opioid crisis and other addictive disorders. 

He said at the time: “The medical implications of cannabis have been neglected for far too long. Now, the time has come for the same rapid investigation into the medical implications of psilocybin.”

With the additional funding soon to be in place, Numinus (TSX-V:NUMIis ready to pioneer exciting new treatments in the mental health arena.

Alongside Dr Wood, Numinus’ Chief Executive, Payton Nyquvest, has assembled a stellar medical and research team.

A notable team member, working under Dr Wood on the Numinus R&D team, is Medical Director Dr Devon Christie, who is trained to deliver MDMA-based psychotherapy for treating PTSD with California’s Multidisciplinary Association for Psychedelic Studies (MAPS).

Dr Christie is joined by senior research scientists Dr Kristina Grotzinger, a phytochemist and lecturer, and Dr Bernd O Keller, an author of over 30 peer-reviewed publications and former director of mass spectrometry at Queen’s University in Ontario. 

Now that Numinus (TSX-V:NUMIhas been given the greenlight to standardize the extraction of psilocybin from mushrooms, this team is primed and ready to push forward.

Working from the 7,000 sq. ft. Numinus Bioscience research facility and laboratory, Grotzinger and Keller are now focused on developing a proprietary extraction method to allow for consistent dosing and application of naturally produced psilocybin. 

“There are two psilocybin protocols in particular that we’re supporting,” says Nyquvest. “One is for psilocybin for alcohol and stimulant addiction and the other is for opioid addiction. We are planning initiatives around what is called ‘Compassionate Access.”  

Similar to expanded access in the US, this is a treatment option supported by regulators like the European Medicines Agency and the FDA that allows companies to provide their experimental drugs to people outside of clinical trials.

Through Compassionate Access, Numinus (TSX-V:NUMIwould gain the ability to start using psychedelic substances in treatment in a pre-approval setting, vastly speeding up its research results. 

“We’ve already applied to the Canadian Institute of Health Research for a grant which, if approved, will provide federal funding support for development of an MDMA-based compassionate access protocol,” 

says Nyquvest. 

The shame and stigma around mental health issues is fading, and it’s mission-driven companies like Numinus (TSX-V:NUMIleading the charge to bring once hidden treatments into the light. 

At the same time, patients are becoming increasingly well-educated and the demand for enhanced treatment options is rising by the day. 

The future of psychedelic-assisted therapies as a tool for treating mental health issues is in sight.

With funding in place, Numinus (TSX-V:NUMIpromises to be one of its chief architects.

READ OUR SPECIAL REPORT -To discover how Numinus’ (TSX-V:NUMI) expert team is at the forefront of developing healing treatments for the mind


Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Numinus Wellness Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and thirty six thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here: https://www.valuethemarkets.com/disclaimer/ . If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

Ben Turney

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

Ben Turney does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney has been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.


In this article:

Author: James Moore

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter